Direct compression of prednisolone base into immediate-release tablets places the API particle-size distribution and bulk density between 0.25 g/mL and 0.45 g/mL as the primary control variables. A representative 5 mg dose in a 120 mg tablet core corresponds to 4.17% w/w, while a 20 mg dose in a 250 mg core corresponds to 8.00% w/w; the dry blend is prepared in a 500 L bin blender operating at 10–12 rpm for 15–20 min at a fill volume of 50–65%, using a 1:5 geometric pre-blend of API with microcrystalline cellulose before the main blending step to accommodate the low-dose fraction. The compression stage is operated on a rotary tablet press with weight variation held below 2% RSD, and the process is validated against the USP Prednisolone Tablets monograph, USP <711> Dissolution, USP <905> Uniformity of Dosage Units, and cleaning validation under 21 CFR 211.67. Direct compression may fail content uniformity when the API particles exceed D90 50 µm, because the low-dose fraction below 2% w/w segregates during bin-to-press transfer; therefore a 1:5 pre-blend is not optional at this dilution. The terminal finished product is an immediate-release oral tablet, typically 5 mg, 10 mg, or 20 mg, with a compendial dissolution medium of 900 mL water and an acceptance criterion of 80% (Q) at the monograph-specified sampling time. Magnesium stearate above 0.5% w/w or lubrication beyond 5 min is avoided because over-lubrication reduces aqueous wetting of the practically water-insoluble base and slows dissolution rate in a predictable, measurable manner.

What Limits Segregation Risk in Low-Dose Prednisolone Capsule Filling?

At API fractions below 5% w/w, low-dose capsule filling with prednisolone base is governed less by blend time than by the ratio of API particle diameter to filler particle diameter, because a 5 mg fill in a size 3 HPMC capsule with total mass 150 mg yields only 3.33% w/w and creates a substantial segregation boundary in the hopper. The process uses a 1:5 API-to-diluent pre-blend passed through a 500 µm screen before the main mixing step in a 200 L V-blender at 20 rpm for 10 min, then automatic tamping-pin capsule filling with pin compaction set to produce a powder plug density of 0.55–0.70 g/mL. Compliance is established through USP <905> Uniformity of Dosage Units, USP <711> Dissolution, and in-process control under 21 CFR 211.110; cleaning validation is performed under 21 CFR 211.67. The API must be controlled at D90 ≤ 45 µm for the 5 mg capsule fill, and if the API-to-filler median diameter ratio exceeds 10:1, hopper-induced fines migration produces subpotent and superpotent capsules without changing the total blend assay. The terminal finished product is an oral capsule with 5 mg or 10 mg labeled content, where dissolution is tested in 900 mL water using the compendial apparatus specified in the finished product monograph. Residual API after cleaning is monitored by a validated HPLC limit rather than visual inspection, because the sub-micron fraction of a corticosteroid powder can remain in seals and gaskets and cannot be judged by appearance.

For prednisolone base formulated as granules in single-dose sachets or as the powder bed for later reconstitution, wet granulation is selected when the API fraction is below 1.0% w/w and dry blending cannot consistently meet USP <905> dose uniformity. A representative batch uses 5 mg prednisolone base in a 1.0 g granule sachet, giving 0.50% w/w API; the granulation fluid is a 3% w/w hypromellose solution added to a high-shear mixer with impeller speed 300–500 rpm and chopper speed 1500–2500 rpm until the wet-mass endpoint reaches an impeller power increase of 15–20% above the dry baseline. The wet granules are dried in a fluid-bed dryer at inlet air temperature 50–60°C to a loss-on-drying of 1.5–2.5%, then sieved through a 1.0 mm mesh to remove oversize agglomerates. Compliance is established through USP <921> Water Determination for the dried granules, USP <711> for the reconstituted suspension, and 21 CFR 211.67 for equipment cleaning; the sachet filling line uses auger feed with fill weight 1.00 g ± 3%. Over-granulation to a bulk density above 0.65 g/mL or moisture above 2.5% is associated with slow reconstitution and particle settling after dispersion, so the granulation endpoint is measured by power draw and post-dry flow rather than judged visually. The terminal finished product is an oral granule in a single-dose sachet, reconstituted to 5 mg/5 mL oral suspension before administration.

When the API Is Micronized for Sterile Aqueous Suspension Injection

Because terminal steam sterilization at 121°C for 15 min is generally unsuitable for aqueous corticosteroid suspensions, injectable prednisolone base is processed by aseptic suspension and filling rather than by post-fill thermal sterilization. The downstream process begins with jet-mill micronization of the API to a D90 not exceeding 10 µm, followed by dispersion in a sterile vehicle containing a viscosity modifier such as sodium carboxymethylcellulose and a wetting agent; the suspension is aseptically filled through a vial-filling line using continuous agitation at 15–25°C. The formulation addition ratio is typically expressed as 10–40 mg/mL of prednisolone base, equivalent to 1.0–4.0% w/v; published data for this specific configuration is limited, so the target concentration must be justified by the intended intramuscular or intra-articular dose and by the syringeability specification of the finished product. Compliance is governed by EU GMP Annex 1 for aseptic processing, USP <71> Sterility Tests, USP <788> Particulate Matter in Injections, and 21 CFR 211.113 for sterile drug products; environmental monitoring in the filling zone is performed at ISO Grade 5. The terminal finished product is a sterile injectable suspension in a single-dose vial or prefilled syringe; it is not suitable for intravenous administration because the particulate fraction would exceed the aqueous-solution limits defined in USP <788>. Line hold times must be validated because recirculation can cause crystal attrition and settling that changes the delivered dose at the end of the fill, and this drift is measured by periodic in-process particle-size testing during filling campaigns.

Gastro-Resistant Tablet Coating and pH-Triggered Release

In gastro-resistant tablet manufacturing, the core is compressed by direct compression as described for immediate-release tablets, but the core is coated with a methacrylic acid copolymer dispersion applied in a perforated pan coater to a weight gain of 6–8% w/w; the coating is sprayed at an inlet air temperature of 45–60°C and atomizing air pressure of 0.5–1.5 bar to avoid polymer coalescence on the tablet surface. The API addition ratio in the core remains 4.17% w/w for a 5 mg dose in a 120 mg core, with the gastro-resistant coating contributing an additional 7–10 mg to the core mass. Compliance is established with USP <711> using a two-stage dissolution test: 2 h in 0.1 N HCl acid stage followed by pH 6.8 phosphate buffer; the acid-stage release is limited to not more than 10% of the labeled amount to confirm the coating integrity. Cleaning validation remains under 21 CFR 211.67, and residual solvent testing is based on ICH Q3C limits for the coating solvents; the process cannot be conducted with excessive tablet-bed moisture, because the methacrylic acid copolymer becomes tacky at product temperatures above 35°C, leading to twin-tablet sticking and coat defects. The terminal finished product is a gastro-resistant oral tablet for delayed release of prednisolone base in the proximal intestine, intended to reduce gastric contact rather than to modify systemic absorption rate beyond the compendial dissolution specification.

Powder for Oral Suspension Requires Reconstitution-Time Viscosity Control

When prednisolone base is filled into a dry powder for oral suspension, the powder moisture specification is set below 1.5% w/w because the reconstituted product is an aqueous suspension in which the practically water-insoluble base must remain uniformly dispersed. A representative batch is prepared by blending 100 mg prednisolone base into 19.9 g of a sucrose-based powder vehicle, giving 0.50% w/w in the dry powder and 0.1% w/v after reconstitution when the bottle is brought to 100 mL with purified water. The process uses a low-shear tumble blender at 10–15 rpm for 15 min, followed by screening through an 850 µm mesh to remove agglomerates; the powder is filled volumetrically with weight control at ±2% of the target 20.0 g. Compliance is evaluated with USP <711> for the reconstituted suspension and USP <921> for the powder moisture, and equipment cleaning is governed under 21 CFR 211.67. The suspension must develop a viscosity of approximately 50–150 mPa·s at 25°C after 60 s of manual shaking; if the viscosity is below 50 mPa·s, the base settles and produces subpotent doses, while above 150 mPa·s the suspension is difficult to pour and rinse from the bottle. Published data for this specific configuration is limited, but the API particle size is typically controlled at D90 ≤ 30 µm to reduce sedimentation velocity. The terminal finished product is a reconstituted oral suspension labeled as 5 mg/5 mL, intended for oral administration after reconstitution with purified water.